ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
ANIP on Nasdaq
Shares outstanding
22,278,088
Price per share
$78.94
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
20,389,327
Total reported value
$1,867,651,891
% of total 13F portfolios
0%
Share change
+484,082
Value change
+$52,979,801
Number of holders
265
Price from insider filings
$78.94
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 11% $230,596,038 2,517,424 BlackRock, Inc. 30 Sep 2025
Meridian Venture Partners II GP, L.P. 4.8% -12% $66,419,394 -$9,630,000 1,034,570 -13% Robert E. Brown, Jr. 21 Aug 2025
MILLENNIUM MANAGEMENT LLC 3.8% -28% $57,136,569 -$19,037,261 818,341 -25% Millennium Management LLC 31 Mar 2025
INTEGRATED CORE STRATEGIES (US) LLC 0.3% -98% $5,976,442 -$96,309,614 65,245 -94% Millennium Management LLC 30 Sep 2025

As of 30 Sep 2025, 265 institutional investors reported holding 20,389,327 shares of ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP). This represents 92% of the company’s total 22,278,088 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP) together control 57% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 2,548,892 -1.2% 0% $233,478,507
VANGUARD GROUP INC 5.7% 1,277,470 +0.01% 0% $117,016,252
STATE STREET CORP 3.2% 711,708 -0.62% 0% $65,192,453
Global Alpha Capital Management Ltd. 2.8% 630,590 -27% 3.3% $57,762,044
UBS Group AG 2.6% 589,874 +46% 0.01% $54,032,458
CITADEL ADVISORS LLC 2.6% 580,085 +1.8% 0.04% $53,135,786
DIMENSIONAL FUND ADVISORS LP 2.3% 505,428 -8.7% 0.01% $46,297,714
GEODE CAPITAL MANAGEMENT, LLC 2.1% 458,014 +7.1% 0% $41,959,481
Deep Track Capital, LP 2% 450,000 -36% 1.2% $41,220,000
Point72 Asset Management, L.P. 1.8% 399,092 0.08% $36,556,814
Nuveen, LLC 1.8% 395,075 +6.5% 0.01% $36,188,870
GOLDMAN SACHS GROUP INC 1.7% 379,026 +84% 0.01% $34,718,781
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.6% 360,178 0.02% $32,992,305
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.6% 348,680 -29% 0.08% $31,939,088
Rubric Capital Management LP 1.5% 343,414 +33% 0.42% $31,456,722
Soleus Capital Management, L.P. 1.5% 340,243 +571% 1.7% $31,166,259
TANG CAPITAL MANAGEMENT LLC 1.4% 317,500 0% 1.1% $29,083,000
AMERIPRISE FINANCIAL INC 1.3% 291,841 -24% 0.01% $26,732,635
MACQUARIE GROUP LTD 1.3% 291,129 -31% 0.03% $26,667,000
Balyasny Asset Management L.P. 1.3% 286,149 +2786% 0.05% $26,211,248
RENAISSANCE TECHNOLOGIES LLC 1.2% 272,902 +113% 0.03% $24,997,823
Ranger Investment Management, L.P. 1.2% 271,345 -49% 1.7% $24,855,202
Aberdeen Group plc 1.2% 269,678 -26% 0.04% $24,702,504
DEUTSCHE BANK AG\ 1.1% 252,568 +14% 0.01% $23,135,229
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 235,661 -8.5% 0% $21,586,548

Institutional Holders of ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 509,349 $40,252,807 +$9,213,847 $78.94 15
2025 Q3 20,389,327 $1,867,651,891 +$52,979,801 $91.60 265
2025 Q2 19,725,780 $1,287,090,849 -$20,870,018 $65.25 229
2025 Q1 19,963,692 $1,336,584,283 +$48,405,121 $66.95 226
2024 Q4 19,278,460 $1,065,666,126 +$20,364,527 $55.28 204
2024 Q3 18,878,833 $1,126,182,384 +$220,571,922 $59.66 207
2024 Q2 15,122,528 $963,007,127 +$64,529,569 $63.68 200
2024 Q1 14,090,492 $974,037,268 +$37,316,448 $69.13 195
2023 Q4 13,616,342 $750,788,600 +$15,033,397 $55.14 180
2023 Q3 13,199,659 $766,379,240 +$52,240,515 $58.06 184
2023 Q2 12,299,725 $662,081,429 +$105,431,062 $53.83 169
2023 Q1 10,365,411 $411,702,884 +$7,764,406 $39.72 137
2022 Q4 10,254,354 $412,610,775 +$2,387,720 $40.23 125
2022 Q3 10,269,268 $330,253,290 +$12,871,843 $32.14 115
2022 Q2 9,879,095 $293,397,646 +$29,894,218 $29.67 109
2022 Q1 9,205,000 $258,822,043 -$5,750,270 $28.11 115
2021 Q4 8,972,675 $413,375,358 +$78,226,286 $46.08 126
2021 Q3 7,280,546 $238,830,760 +$14,353,157 $32.82 105
2021 Q2 7,204,407 $252,488,638 -$2,871,513 $35.05 104
2021 Q1 7,293,016 $263,483,493 +$391,549 $36.14 100
2020 Q4 7,361,043 $213,798,867 +$1,986,104 $29.04 109
2020 Q3 7,312,777 $206,302,713 -$6,295,496 $28.21 105
2020 Q2 7,466,801 $241,329,748 -$25,517,337 $32.34 124
2020 Q1 7,973,561 $324,820,687 -$11,764,194 $40.74 135
2019 Q4 8,093,378 $499,022,609 -$70,945,248 $61.67 161
2019 Q3 9,115,689 $664,230,757 +$37,860,037 $72.88 181
2019 Q2 8,576,026 $705,083,478 +$79,655,054 $82.20 190
2019 Q1 7,702,646 $543,125,675 +$45,892,557 $70.54 183
2018 Q4 7,079,477 $318,725,901 -$18,340,193 $45.02 158
2018 Q3 7,500,122 $423,927,111 +$15,362,009 $56.54 164
2018 Q2 7,191,053 $480,388,569 +$39,751,902 $66.80 179
2018 Q1 6,622,638 $385,621,004 +$5,056,635 $58.22 166
2017 Q4 6,543,742 $421,877,087 +$7,855,697 $64.45 152
2017 Q3 6,413,607 $336,579,902 -$1,240,416 $52.49 135
2017 Q2 6,496,859 $305,032,164 +$451,131 $46.80 145
2017 Q1 6,453,052 $319,499,983 +$59,803,632 $49.51 151
2016 Q4 6,252,710 $379,236,629 +$11,513,195 $60.62 151
2016 Q3 6,033,380 $400,349,646 +$29,865,427 $66.35 166
2016 Q2 5,605,143 $312,867,690 +$11,945,824 $55.82 134
2016 Q1 5,798,068 $195,120,743 -$21,503,997 $33.66 115
2015 Q4 6,319,783 $285,412,733 -$31,094,929 $45.12 119
2015 Q3 6,966,028 $275,308,091 +$16,995,961 $39.51 118
2015 Q2 6,494,641 $402,533,646 -$29,199,720 $62.05 120
2015 Q1 6,959,392 $434,650,108 +$84,590,578 $62.55 124
2014 Q4 5,627,718 $317,206,714 +$97,075,054 $56.39 99
2014 Q3 4,525,202 $128,520,656 -$2,966,635 $28.28 69
2014 Q2 4,487,871 $154,563,359 +$28,391,675 $34.44 78
2014 Q1 3,764,373 $118,010,408 +$77,289,139 $31.35 64